In addition, 24 h after the last FGF1 injection of a chronic 2-week treatment regimen, which reduced hepatic steatosis by approximately 50% (data not shown), plasma TG levels were increased to a similar extent compared to a single acute injection, indicating that adaptation to FGF1 treatment does not develop within this time frame (Fig. S2A). The gene discussed is FGF1; the disease is Hepatic steatosis.